ASCO 2020: Ovarian Cancer
Filter Results
Neoadjuvant Chemotherapy & Increase of Blood Clots in Ovarian Cancer
Women who are on neoadjuvant chemotherapy (NACT) for advanced ovarian cancer may have increased risk for blood clots, according to a study presented at ASCO 2020 virtual scientific sessions (Abstract 6073).
Financial Toxicity Among Women With Recurrent Ovarian Cancer
A recent study found recurrent ovarian cancer patients who reported high financial toxicity also demonstrated higher mean scores for depression and anxiety, as well as persistently lower quality of life.
Cediranib + Olaparib for Recurrent Platinum-Sensitive Ovarian Cancer
Findings from a phase III study showed that cediranib plus olaparib had similar activity to standard platinum-based chemotherapy in relapsed platinum-sensitive ovarian cancer, according to data presented at the ASCO 2020 Annual Meeting (Abstract 6003).
Understanding the Impact of Chronotype Among Ovarian Cancer Survivors
New data suggests that ovarian cancer survivors with late chronotypes reported higher levels of pain, which was associated with poorer sleep and diet quality as well as higher levels of inflammation and insulin, according to findings presented at the ASCO 2020 Annual Meeting (Abstract 6018).
Study Emphasizes Importance of Symptom Awareness in Ovarian Cancer Diagnosis
A nested case control study found that certain recurring symptoms associated with the abdominal and pelvic areas, as well as pain, appear to indicate an association with ovarian cancer, according to finding presented at the ASCO 2020 Annual Meeting (Abstract 6063).
Secondary Hematologic Malignancies & Ovarian Cancer Patients Treated With PARP Inhibitors
A meta-analysis demonstrated that the risk of secondary hematologic malignancies was not significantly increased among ovarian cancer patients who were treated with PARP inhibitors compared to a control arm, while still attaining survival benefits, according to findings presented at the ASCO 2020 Annual Meeting (Abstract 12076).
Long-Term Responses to Rucaparib in Recurrent Ovarian Cancer
A recent analysis found that long-term responders to rucaparib include ovarian cancer patients with BRCA mutation, particularly homozygous deletion or rearrangements, as well as BRCA1 hypermethylation, and RAD51C/D mutations, according to findings presented at the ASCO 2020 Annual Meeting (Abstract 6015).
A Novel Testing & Prevention Model for Hereditary Ovarian & Breast Cancer
New data showed that a rural model for the screening and prevention of at-risk patients for hereditary breast and ovarian cancer detects pathogenic mutations in unaffected patients prior to diagnosis, according to a presentation from the ASCO 2020 Annual Meeting (Abstract 1575).